FLT3 and acute myeloid leukemia: Other known AML driver mutations, such as fms-like tyrosine kinase 3 (FLT3) and nucleophosmin 1 (NPM1), are notably absent from these preleukemic HSCs and likely occur later, at the time of leukemic transformation [152,153].